Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
Resignation of Alessandra Daigneault as Chief Corporate Officer, General Counsel
and Corporate Secretary
On May 19, 2022, Ms. Alessandra Daigneault tendered her resignation as Chief
Corporate Officer, General Counsel and Corporate Secretary of NRx
Pharmaceuticals, Inc. (the "Company") effective on July 18, 2022 or such earlier
date as may be agreed with the Company. Ms. Daigneault is leaving the Company to
pursue other personal and professional interests.
The Company's interim Chief Executive Officer, Mr. Robert Besthof, expressed his
thanks to Ms. Daigneault for her outstanding contributions to the Company,
including overseeing the merger of NeuroRx, Inc, and Big Rock Partners
Acquisition Corp in May 2021, which resulted in the formation of the Company.
Mr. Michael Kunz, the Company's Deputy General Counsel, is expected to assume
the duties of General Counsel and Corporate Secretary.
Resignation of Mr. Ira Strassberg as Chief Financial Officer and Treasurer
On May 19, 2022, Mr. Ira Strassberg tendered his resignation as Chief Financial
Officer and Treasurer of the Company effective July 18, 2022. Mr. Strassberg is
leaving the Company to pursue other personal and professional interests. Mr.
Strassberg will continue to fulfill his duties as Chief Financial Officer and
Treasurer of the Company until his departure. The Board will be conducting a
search for a successor.
The Chairman of the Company's Audit Committee, Mr. Patrick Flynn, and Mr.
Besthof, expressed their thanks to Mr. Strassberg for his meaningful
contributions to the Company, including the establishment of robust internal
controls and a strong finance and accounting function at the Company.
2
© Edgar Online, source Glimpses